Q4 2024 Edwards Lifesciences Corp Earnings Call Transcript
Key Points
- Edwards Lifesciences Corp (EW) reported a strong 9% sales growth for the full year 2024, reaching $5.4 billion, in line with their original guidance.
- The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment exceeded expectations, contributing significantly to the company's growth.
- Strategic acquisitions, including JC Medical, Innovalve, and Endotronix, expanded Edwards' opportunities in new therapeutic areas.
- The company completed the sale of its Critical Care segment, allowing a focused strategy on structural heart technologies.
- Edwards Lifesciences Corp (EW) maintained a strong balance sheet with approximately $3 billion in cash and cash equivalents as of December 31, 2024.
- Transcatheter Aortic Valve Replacement (TAVR) growth was lower than expected, impacting overall sales performance.
- Sales growth in Japan was slower compared to other regions, indicating regional pressure and challenges.
- The company experienced a decrease in adjusted gross profit margin from 80% to 79% year-over-year.
- Selling, general, and administrative expenses increased significantly, reflecting growth in TMTT field-based teams and transition expenses.
- Foreign exchange rates are expected to negatively impact 2025 sales by approximately $130 million.
Greetings, and welcome to the Edwards Lifesciences Corporation fourth-quarter 2024 results.
(Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce you to your host, Mark Wilterding, SVP of Global Finance. Thank you, Mark. You may begin.
Thank you, Alicia. Good afternoon, and thank you all for joining us.
With me on today's call is our CEO, Bernard Zovighian, and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Larry Wood, our Global Group President of TAVR and Surgical; Daveen Chopra, our global leader of TMTT; and Wayne Markowitz, our global leader of Surgical. Just after the close of regular trading, Edwards Lifesciences released fourth-quarter 2024 financial results.
During today's call, management will discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
